Marlborough, Mass.-based Boston Scientific said the new stent uses a resorbable polymer with an ultrathin everolimus coating, technology it also used with the Synergy stent.
“We are taking the best of our Synergy stent and applying it to our new, fully resorbable scaffold technology,” interventional cardiology president Kevin Ballinger said in prepared remarks. “We continue to invest in meaningful innovations designed to provide better outcomes for patients with coronary artery disease.”
Boston Scientific said the 1st patients in the study were enrolled by primary investigator Dr. Ian Meredith of the Monash Medical Centre in Melbourne, Australia.
“By virtue of its unique design properties, incorporating thinner struts and enabling greater stent expansion while maintaining radial strength, this fully resorbable scaffold technology may potentially overcome a number of limitations with first generation absorbable scaffolds,” Meredith said.